By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Up Close and Very Personal with Your Brain
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Up Close and Very Personal with Your Brain
DiagnosticsMedical InnovationsNewsRadiologySpecialtiesTechnology

Up Close and Very Personal with Your Brain

Steve Goldstein
Steve Goldstein
Share
4 Min Read
SHARE

Dementia is a growing problem and a huge burden on the health care system. Approximately 14 percent suffer worldwide and the prevalence among those 80 years of age and older is 24 percent. Alzheimer’s disease is now the sixth leading cause of death in the United States, with some estimates suggesting one person develops Alzheimer’s every 68 seconds. Deaths from this disease have increased 66 percent between 2000 and 2008 and there are now an estimated 5.4 million cases of Alzheimer’s domestically and 35 million worldwide.

Dementia is a growing problem and a huge burden on the health care system. Approximately 14 percent suffer worldwide and the prevalence among those 80 years of age and older is 24 percent. Alzheimer’s disease is now the sixth leading cause of death in the United States, with some estimates suggesting one person develops Alzheimer’s every 68 seconds. Deaths from this disease have increased 66 percent between 2000 and 2008 and there are now an estimated 5.4 million cases of Alzheimer’s domestically and 35 million worldwide.

Typically, Alzheimer’s has been difficult to diagnose, with certainty often not available until autopsy. So when new imaging technologies appear that may help detect Alzheimer’s, notice is taken. At the SNM annual meeting in Miami, Siemens Healthcare is demonstrating and extolling its integrated amyloid imaging solution, a combination of hardware and software as well as a reliable imaging biomarker. Amyloids are proteins that create plaque in the brain, inhibiting neurons, in much the same way that arterial plaque causes heart disease.

The first element of the solution is the Biograph mCT positron emission tomography/computer tomography (PET-CT) system. What’s interesting about this machine is that it can reportedly differentiate between gray and white brain matter with higher resolution that can not only visualize the uptake of amyloids but quantify the uptake.

More Read

Boston Scientific Receives FDA Approval of New Spinal Cord Implant System to Manage Pain
Welcome to the Affordable Care Act Call Center, Please Press One for Healthcare, Two for….
Navigating Dental Insurance: Maximizing Your Benefits For Treatment
Spring Allergies? Check Out These 9 Natural Allergy Remedies
6 Reasons You Should Visit An Orthodontist

Alexander R. Zimmermann, Siemen’s vice president of marketing and sales for molecular imaging, said that the Biograph is a key part of a puzzle they’ve been working on for nearly six years.

“We’re very happy to introduce the world’s first integrated solution for amyloid imaging, which consists of the availability, manufacturing and distribution of a new imaging biomarker for amyloid uptake in the brain, a scanner that is made to visualize this marker with a higher volumetric resolution and a probability of quantification, and an FDA-pending software that will offer a ratio analysis,” he said in an interview. “We believe this is revolutionary because it’s offering for the first time a PET visualization of amyloids and therefore supports early insights into the diagnosis of Alzheimer’s.”

Nine U.S. medical facilities already have the Biograph, with another 16 slated to have installations by year’s end.

Siemen’s was mum about the biomarker component of the integrated solution because it is being developed and shepherded by Eli Lilly and Company under the trade name Amyvid. Lilly is close-holding the information, but we’ve asked for comment.

 

 

 

 

 

TAGGED:Alzheimer's Diseasebiograph
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

The Fiction Behind The Cost of New Drugs

February 18, 2012

Seeing Red for Heart Health

February 3, 2013
Specialties

How to Have an Easier Period while Staying Eco-Friendly

January 2, 2019
Technology

Why Spending 72 Hours Without Technology is Healing

October 26, 2024
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?